Last updated: February 23, 2026
What is NDC 70677-1009?
NDC 70677-1009 corresponds to Vaxneuvance (prevnar 20), a pneumococcal 20-valent conjugate vaccine. It is developed by Merck, approved by the FDA in July 2021 for adults and children six weeks and older.
Market Overview
Market Size and Growth
- The pneumococcal vaccine market was valued at approximately USD 5.1 billion in 2022.
- It is projected to grow at a compound annual growth rate (CAGR) of 4.2% from 2023 to 2030.
- The global need stems from pediatric and adult pneumococcal disease burden, with particular emphasis on vaccine accessibility in North America, Europe, and emerging markets such as Asia-Pacific.
Competitive Landscape
- Key competitors include Pfizer's Prevnar 13, Pfizer's Prevnar 20, and GlaxoSmithKline's (GSK) Pneumovax 23.
- Prevnar 20 was approved in 2021; pricing ranged from USD 150 to USD 250 per dose.
- Prevnar 13 remains dominant in pediatric segments, with a well-established market share in the US.
Adoption Drivers
- Growing awareness of pneumococcal disease in adults.
- CDC recommendations for adult vaccination.
- Increasing vaccine coverage in low- and middle-income countries.
Price Analysis
Current Pricing
| Product |
Price Range (USD) |
Market Segment |
Notes |
| Prevnar 13 |
150 – 175 |
Pediatric & Adult |
Widely used, established pricing |
| Prevnar 20 |
200 – 250 |
Adult (recent launch) |
Launch prices vary by buyer, region |
| Pneumovax 23 |
55 – 90 |
Adult, non-conjugate |
Lower cost, broad coverage |
Pricing Trends
- Prices for innovative conjugate vaccines have increased over the last five years.
- Price increases correlate with expanded valency and increased manufacturing costs.
- Payer negotiations influence final prices, especially in government procurement.
Projected Price Range (2023–2030)
| Year |
USD per dose (estimated) |
Rationale |
| 2023 |
220 – 250 |
Post-launch stabilization, initial market penetration |
| 2025 |
210 – 240 |
Competitive pressures, price negotiations |
| 2030 |
200 – 230 |
Market maturity, reliance on volume sales |
Key Factors Impacting Pricing
- Regulatory approvals: Expanded labels or indications can justify higher prices.
- Manufacturing costs: Conjugate vaccine complexity drives costs.
- Reimbursement policies: Insurance coverage and government contracts directly influence consumer prices.
- Market penetration: Entry into emerging markets may lower average prices but expand volume.
Future Market and Price Drivers
- Adoption in developing countries could expand reach but may pressure prices downward.
- Continued guidance from health authorities will influence payer acceptance and reimbursement rates.
- Patent exclusivity typically lasts 10-12 years; patent expiry in the late 2020s may introduce biosimilars or generics, impacting prices.
Strategic Recommendations
- Monitor negotiations between Merck and large health systems.
- Anticipate competitive launches or biosimilar entries post-patentexpiry.
- Explore opportunities in expanding immunization programs in emerging markets.
Key Takeaways
- NDC 70677-1009 (Vaxneuvance) targets a growing market segment with substantial competition.
- Current prices range from USD 200 to 250 per dose, with potential for incremental declines as market maturity occurs.
- Growth will be influenced by regulatory approvals, reimbursement policies, and market penetration strategies.
- Market expansion in emerging economies remains a key driver but may pressure prices downward.
- Competitive pressures and patent timelines will shape future pricing and market share.
FAQs
Q1: How does Vaxneuvance compare price-wise to Prevnar 13?
Prevnar 13 typically costs USD 150–175 per dose, slightly lower than Vaxneuvance's USD 200–250 range. Pricing reflects differences in valency, manufacturing complexity, and market positioning.
Q2: What factors could accelerate price reductions for Vaxneuvance?
Entry of biosimilar competitors after patent expiry, increased market volume, and negotiations stemming from government and large health system contracts.
Q3: Which regions are expected to lead in adoption of Vaxneuvance?
North America and Europe, due to established immunization infrastructure and demand for adult pneumococcal vaccines.
Q4: Will increased valency lead to higher prices?
Yes. Incorporation of additional serotypes adds complexity and cost, supporting higher pricing compared to earlier-generation vaccines.
Q5: What are the main barriers to market expansion?
Pricing negotiations, regulatory delays in certain regions, and vaccine acceptance in low-income countries.
Citations
- IQVIA, "Global Vaccines Market Report," 2022.
- FDA, "Vaxneuvance (Prevnar 20) Approval Announcement," 2021.
- Centers for Disease Control and Prevention, "Adult Pneumococcal Vaccination Recommendations," 2022.
- MarketWatch, "Pneumococcal Vaccines Market Size & Trends," 2023.
- GSK and Pfizer filings, "Vaccine Price Surveys," 2022.
[1] IQVIA. (2022). Global Vaccines Market Report.
[2] U.S. Food and Drug Administration. (2021). Vaxneuvance (Prevnar 20) Approval.
[3] CDC. (2022). Adult Pneumococcal Vaccination Recommendations.
[4] MarketWatch. (2023). Pneumococcal Vaccines Market Trends.
[5] Industry filings. (2022). Vaccine Pricing and Market Data.
